In Quest To Transform Biotech, Moderna Secures $110M To Get Into Clinic
This article was originally published in The Pink Sheet Daily
Executive Summary
This biotech envisions a day when messenger RNA therapeutics enable a patient’s body to produce needed proteins in vivo, thereby vastly expanding the universe of druggable targets and bypassing all of the patented large-molecule drugs that are the industry’s foundation.